Detalhe da pesquisa
1.
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation.
J Immunother Cancer
; 12(5)2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38702145
2.
Tolerability of obinutuzumab therapy in patients with rituximab-relapsed/refractory B-cell malignancies - a retrospective single center cohort study.
Oncotarget
; 9(52): 29944-29956, 2018 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30042825